2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
暂无分享,去创建一个
Jennifer G. Robinson | Patrick McBride | Karol Watson | C Noel Bairey Merz | Alice H Lichtenstein | Neil J Stone | P. Wilson | R. Eckel | D. Gordon | Sidney C. Smith | K. Watson | D. Lloyd‐Jones | J. Robinson | N. Stone | A. Lichtenstein | C. N. Bairey Merz | C. Blum | A. Goldberg | D. Levy | P. McBride | J. Schwartz | Susan T. Shero | Sidney C Smith | Donald M Lloyd-Jones | Peter W F Wilson | Robert H Eckel | Daniel Levy | Jennifer G Robinson | David Gordon | Anne C Goldberg | Conrad B Blum | J Sanford Schwartz | Susan T Shero | C. B. Bairey Merz | P. Mcbride | C. Bairey Merz | P. Wilson
[1] R. Brook,et al. Secondary causes of dyslipidemia. , 2012, The American journal of cardiology.
[2] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.
[3] C. E. Becker. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.
[4] A. Gotto,et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. , 2010, The American journal of cardiology.
[5] N. Wenger,et al. End-of-life decision making , 2000, Journal of General Internal Medicine.
[6] M. Tinetti,et al. Health outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. , 2011, Archives of internal medicine.
[7] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[8] Diane Lacaille,et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .
[9] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.
[10] Harlan M Krumholz,et al. Cardiac care for older adults. Time for a new paradigm. , 2011, Journal of the American College of Cardiology.
[11] J. Hippisley-Cox,et al. Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. , 2005, The British journal of general practice : the journal of the Royal College of General Practitioners.
[12] M. Hennerici,et al. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack , 2009, Neurology.
[13] P. Macfarlane,et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study , 2009, Journal of Neurology.
[14] C. White,et al. Impact of statin dosing intensity on transaminase and creatine kinase. , 2007, The American journal of medicine.
[15] A. Gotto,et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.
[16] S. Studenski,et al. Angiotensin‐Converting Enzyme Inhibitor and Statin Use and Incident Mobility Limitation in Community‐Dwelling Older Adults: The Health, Aging and Body Composition Study , 2011, Journal of the American Geriatrics Society.
[17] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[18] H. Origasa,et al. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS). , 2003, American heart journal.
[19] Jennifer G. Robinson,et al. Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? , 2007, Stroke.
[20] Janusz Wnek,et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.
[21] R. Varadhan,et al. Support of personalized medicine through risk-stratified treatment recommendations - an environmental scan of clinical practice guidelines , 2013, BMC Medicine.
[22] S. Greenfield,et al. COMMITTEE ON STANDARDS FOR DEVELOPING TRUSTWORTHY CLINICAL PRACTICE GUIDELINES , 2011 .
[23] G. Alexander,et al. Reconsidering medication appropriateness for patients late in life. , 2006, Archives of internal medicine.
[24] M. Drazner,et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[25] J. Crouse,et al. Hypertriglyceridemia: a contraindication to the use of bile acid binding resins. , 1987, The American journal of medicine.
[26] R. Eckel,et al. Treatment of hypertriglyceridemia , 2006, National Institutes of Health consensus development conference summary.
[27] A. Laupacis,et al. Preference-Based Antithrombotic Therapy in Atrial Fibrillation: Implications for Clinical Decision Making , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] Yasuo Ohashi,et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.
[29] Judith S. Hochman,et al. Reprint: 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. , 2013, Journal of the American Pharmacists Association : JAPhA.
[30] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[31] G. Thompson. Recommendations for the use of LDL apheresis. , 2008, Atherosclerosis.
[32] M. Rawlins. De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.
[33] P. Serruys,et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.
[34] John H Fuller,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial , 2004, The Lancet.
[35] Neil J Stone,et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.
[36] M. Jessup,et al. The next steps in developing clinical practice guidelines for prevention. , 2013, Journal of the American College of Cardiology.
[37] P. Macfarlane,et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.
[38] Moshe Levi,et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. , 2011, Circulation.
[39] Marilyn Rantz,et al. Predicting death in the nursing home: development and validation of the 6-month Minimum Data Set mortality risk index. , 2005, The journals of gerontology. Series A, Biological sciences and medical sciences.
[40] L. Cho,et al. Asian Americans and cardiometabolic risk why and how to study them. , 2010, Journal of the American College of Cardiology.
[41] M. Roffi,et al. Current concepts on coronary revascularization in diabetic patients. , 2011, European heart journal.
[42] N. Stone,et al. Goals of statin therapy: three viewpoints. , 2004, Current atherosclerosis reports.
[43] L. Tavazzi,et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.
[44] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[45] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[46] Robert J. Glynn,et al. Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial , 2010, Annals of Internal Medicine.
[47] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[48] F. Veglia,et al. Do statins improve outcomes and delay the progression of non-rheumatic calcific aortic stenosis? , 2011, Heart.
[49] B. Starfield,et al. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. , 2002, Archives of internal medicine.
[50] L. Castilla-Guerra,et al. EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK , 2009, Neurology.
[51] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[52] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[53] D. Mikhailidis,et al. Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) , 2006, Diabetes Care.
[54] The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. , 1984, JAMA.
[55] J. Stamler. Clofibrate and niacin in coronary heart disease. , 1975, JAMA.
[56] J. Stamler,et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. , 1986, Journal of the American College of Cardiology.
[57] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[58] Gert Mayer,et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. , 2009, The New England journal of medicine.
[59] P. Libby,et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.
[60] A. Hartmann,et al. Long‐term Cardiac Outcomes in Renal Transplant Recipients Receiving Fluvastatin: The ALERT Extension Study , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[61] F. Messerli,et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy--a meta-analysis. , 2008, The American journal of cardiology.
[62] Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[63] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[64] M. Barry,et al. Shared decision making--pinnacle of patient-centered care. , 2012, The New England journal of medicine.
[65] N. Paynter,et al. Cardiovascular risk prediction in diabetic men and women using hemoglobin A1c vs diabetes as a high-risk equivalent. , 2011, Archives of internal medicine.
[66] N. Stone,et al. Management of lipids in clinical practice , 1997 .
[67] Samy I McFarlane,et al. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. , 2008, Journal of the cardiometabolic syndrome.
[68] P Glasziou,et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial , 2005, The Lancet.
[69] D. Pryor,et al. Variation in patient utilities for outcomes of the management of chronic stable angina. Implications for clinical practice guidelines. Ischemic Heart Disease Patient Outcomes Research Team. , 1995, JAMA.
[70] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.
[71] R. Collins,et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.
[72] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[73] Elizabeth H Bradley,et al. Understanding the treatment preferences of seriously ill patients. , 2002, The New England journal of medicine.
[74] W. März,et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. , 2005, The New England journal of medicine.
[75] I. Holme,et al. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. , 2007, The American journal of cardiology.
[76] S. Bonovas,et al. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies. , 2007, British journal of clinical pharmacology.
[77] D. Capuzzi,et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. , 2008, The American journal of cardiology.
[78] Irene M Stratton,et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. , 2004, Diabetes care.
[79] W. Lewis,et al. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. , 2010, Preventive cardiology.
[80] R. Eckel. Approach to the patient who is intolerant of statin therapy. , 2010, The Journal of clinical endocrinology and metabolism.
[81] V. Athyros,et al. Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention , 2002, Current medical research and opinion.
[82] R. Collins,et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). , 2005, Diabetes care.
[83] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[84] Edward J. Mills,et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. , 2008, Journal of the American College of Cardiology.
[85] S. Grundy,et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[86] D. Schwertz,et al. High-Dose Statin Therapy for Secondary Prevention of Stroke: Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study Review , 2008, The Journal of cardiovascular nursing.
[87] H. Shimomura,et al. Effects of early statin treatment on symptomatic heart failure and ischemic events after acute myocardial infarction in Japanese. , 2006, The American journal of cardiology.
[88] M. Clearfield. Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.
[89] D. Hunninghake,et al. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.
[90] J. Danks,et al. Fates worse than death: the role of valued life activities in health-state evaluations. , 1996, Health Psychology.
[91] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[92] Adolescents. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2011, Pediatric Clinical Practice Guidelines & Policies.
[93] S. Grundy,et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.
[94] A. Cass. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.
[95] M. Clearfield. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes. , 2005, Current atherosclerosis reports.
[96] M. Lauer,et al. Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute. , 2013, Journal of the American College of Cardiology.
[97] O. Faergeman,et al. Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 versus >or=65 years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study). , 2009, The American journal of cardiology.
[98] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.
[99] F. Sacks,et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. , 2012, The Journal of clinical endocrinology and metabolism.
[100] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[101] Barry R. Davis,et al. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.
[102] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. , 2008, Mayo Clinic proceedings.
[103] Dawei Xie,et al. All‐Cause 1‐, 5‐, and 10‐Year Mortality in Elderly People According to Activities of Daily Living Stage , 2012, Journal of the American Geriatrics Society.
[104] Y. Ohashi,et al. Usefulness of Pravastatin in Primary Prevention of Cardiovascular Events in Women: Analysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA Study) , 2008, Circulation.
[105] H. Bays,et al. Safety considerations with niacin therapy. , 2007, The American journal of cardiology.
[106] L. Prosser,et al. Estimated morbidity and mortality in adolescents and young adults diagnosed with Type 2 diabetes mellitus , 2012, Diabetic medicine : a journal of the British Diabetic Association.
[107] E. Braunwald,et al. Coronary heart disease Acute coronary syndromes and diabetes : is intensive lipid lowering beneficial ? Results of the PROVE IT-TIMI 22 trial , 2006 .
[108] Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. , 2010, American heart journal.
[109] Roger B. Davis,et al. External Validation of an Index to Predict Up to 9‐Year Mortality of Community‐Dwelling Adults Aged 65 and Older , 2011, Journal of the American Geriatrics Society.
[110] M. Tinetti,et al. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. , 2011, Archives of internal medicine.
[111] D. Herrington,et al. Outcomes of Using High- or Low-Dose Atorvastatin in Patients 65 Years of Age or Older with Stable Coronary Heart Disease , 2007, Annals of Internal Medicine.
[112] J. Samet,et al. Food and Drug Administration , 2007, BMJ : British Medical Journal.
[113] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[114] A. Yashin,et al. Age Patterns of Incidence of Geriatric Disease in the U.S. Elderly Population: Medicare‐Based Analysis , 2012, Journal of the American Geriatrics Society.
[115] W. Howard. Effect of Lowering LDL Cholesterol Substantially Below Currently Recommended Levels in Patients With Coronary Heart Disease and Diabetes: The Treating to New Targets (TNT) study , 2008 .
[116] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[117] Paul M. Ridker,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[118] K. Bainey,et al. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. , 2009, Atherosclerosis.
[119] B. G. Brown,et al. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. , 2008, The American journal of cardiology.
[120] D. Simons-Morton,et al. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents: Summary Report , 2016, Pediatric Clinical Practice Guidelines & Policies.
[121] L. Goldman,et al. Adolescent overweight and future adult coronary heart disease. , 2007, The New England journal of medicine.
[122] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[123] A. LaCroix,et al. Statin use and incident frailty in women aged 65 years or older: prospective findings from the Women's Health Initiative Observational Study. , 2008, The journals of gerontology. Series A, Biological sciences and medical sciences.
[124] J. Huttunen,et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.
[125] Paul Welsh,et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. , 2011, JAMA.
[126] Yasuo Ohashi,et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial , 2006, The Lancet.
[127] M. Landray,et al. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment , 2013, European heart journal.
[128] B. Davis,et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.
[129] J Wouter Jukema,et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. , 2010, Archives of internal medicine.
[130] J. Kastelein,et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. , 2008, Journal of the American College of Cardiology.
[131] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[132] Guiding the guidelines , 2011, The Lancet.
[133] J Shepherd,et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials , 2009, BMJ : British Medical Journal.